Swedish Orphan Biovitrum AB and Novimmune SA have entered into an licence agreement for the global rights to an orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis (HLH).
Novartis announced that it has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) regarding their compound MOR106.
Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi's European generics business, by Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion
Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it has agreed to acquire Juniper Pharmaceuticals.
Roche and Foundation Medicine (USA) entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI's common stock not already owned by Roche with a total transaction value of $2.4 billion.
United Therapeutics Corporation and SteadyMed Ltd announced the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed. The transaction is valued at $216 million.